A major issue for many patients presenting to Rheumatology with Ehlers-Danlos syndromes will be pain. This presentation will provide an overview of different pain mechanisms contributing to pain in Ehlers-Danlos syndromes, and an approach to management. Patients may have acute and chronic pain, and there are multiple potential contributing sources of which musculoskeletal pain is just one facet. Therefore in order to approach the management of pain in these patients, it is important to understand the different pain mechanisms that may be contributing. Causes of acute pain may include subluxations, dislocations, musculoskeletal trauma and acute musculoskeletal tension and spasm. Chronic pain may include musculoskeletal and neuropathic pain sources and embrace mechanisms including peripheral and central sensitization with development of centralized chronic widespread pain. This provides a background upon which many other chronic pain syndromes such as fibromyalgia and chronic fatigue frequently overlap. The patients social and psychological status can be significant factors influencing the presentation and engagement with treatment. An appreciation of these different pain mechanisms will inform an individualized pain management approach rooted in a biopsychosocial model, which may include non-pharmacologic treatment strategies as well as pharmacotherapy. The response to medication in patients with chronic pain is often suboptimal, and the benefit of drug treatment has to be balanced against potential acute and long term adverse effects. For patients with significant physical deconditioning, the key treatment strategy is to improve musculoskeletal fitness and tone supporting the hypermobile joints. Many patients with chronic pain will benefit from learning longer term self-managed pain management skills such as pacing, relaxation, sleep hygiene and CBT based treatment. Fatigue is a common patient-identified theme across rheumatic diseases (including rheumatoid arthritis, osteoarthritis, systemic lupus erythematosus, ankylosing spondylitis, primary Sjö gren's syndrome, psoriatic arthritis, systemic sclerosis and fibromyalgia), yet remains inadequately addressed by the medical profession. Research shows this bothersome symptom for patients is often overlooked or dismissed during consultations with patients reliant on self-management strategies. This is often done on a trial and error basis. Fatigue lowers quality of life for patients: impacting on their ability to work, maintain family roles, socialize and participate in leisure activities. In this talk, research from the last decade will be presented which shows the extent of the problem; how fatigue affects patients and their interactions with family, friends and work colleagues; how patients view themselves as a result of fatigue and how patients feel about discussing fatigue with healthcare professionals. Disclosure statement: The author has declared no conflicts of interest.
I05. THE CURRENT YEARS: TESTING NEW INTERVENTIONS

Sarah Hewlett
Nursing and Midwifery, University of the West of England, Bristol, UNITED KINGDOM Fatigue in inflammatory rheumatic diseases is thought to have many interacting causes, therefore requiring different and combined approaches to management and self-management. This presentation will examine the evidence base (or otherwise) for a range of interventions. Disclosure statement: The author has declared no conflicts of interest.
I06. THE FUTURE YEARS: UNRAVELLING THE CAUSAL PATHWAYS
Katie Druce Arthritis Research UK Epidemiology Unit Centre for Musculoskeletal Research, University of Manchester, Manchester, UNITED KINGDOM Fatigue affects up to 80% of patients with rheumatic diseases, but is poorly managed because evidence on the causality of fatigue in RA is conflicting. Existing evidence implicates a number of putative causal variables, including RA disease factors, cognitive and behavioural domains and other personal factors. However, fatigue is a complex and subjective symptom for which it is unlikely a normal progression exists. Instead, it is likely that the course varies between individuals, requiring treatment stratification and tailored interventions. This presentation will address what is currently known about the causal pathways of fatigue and will discuss possible future treatment targets. Furthermore, it will address some of the existing methodological problems which limit our understanding of the symptom's aetiology and identify key areas for future research in the field. Disclosure statement: The author has declared no conflicts of interest.
I07. TREAT TO TARGET IN OSTEOPOROSIS
Cyrus Cooper MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, UNITED KINGDOM Osteoporosis constitutes a major public health problem through its association with age related fractures. These fractures typically occur at the hip, spine and distal forearm. It has been estimated from The treat to target concept has been best exemplified in rheumatoid arthritis, where the target is a critical level of inflammation, the main pathology driving disease manifestations. For osteoarthritis (OA), a clinical syndrome associated with structural joint failure, the questions are: what should be our target domain and what target level of this domain is critical for meaningful patient outcomes? There are therefore a number of possibilities, though it is sadly not clear that we have effective treatments for each domain. Should we treat structural abnormalities in people without symptoms? This would be the ideal scenario for early intervention -but we lack evidence for any existing therapies and the current regulatory hurdles linking structural changes to symptoms mean it will be many years before we see such interventions. What about structural pathologies in people with symptoms? At the joint level, there are a number of potential tissue targets including cartilage, subchondral bone pathologies, meniscal abnormalities and synovitis. Currently our most effective analgesic therapies are those targeting inflammation (NSAIDs and intra-articular corticosteroids) though the relationship between symptom reduction and degree of structural pathology change is not clear. Non-targeted treatment with bisphosphonates did not help OA pain, but there is some evidence to support treatments that are beneficial in reducing symptoms by targeting bone marrow lesions, though large trial data are needed. At the person level, the obvious target is joint pain. This is immediately made more complex by the fact that most people over 50 report a median of 4 painful joints. So which joint should be the target? How will we measure pain? Most tools were developed for group-level trial outcomes, not for individual patient responses. And this has been very complex in clinical trials, let alone in timeconstrained clinical practice. Weight reduction is effective in reducing pain in large joints, and we know the target (often about 10% weight reduction), but have we got the resources to address this broad medical issue? Perhaps a more realistic target that we could focus on immediately is to help people achieve success with their selfselected most valued activity, a construct that involves both reduced pain, improved functioning and attention to self-efficacy principals. A focus on simple muscle strengthening would result in many people achieving such goals. Disclosure statement: The author has declared no conflicts of interest.
I09. TREAT TO TARGET IN LUPUS
Anisur Rahman
Rheumatology, University College London, London, UNITED KINGDOM
The principle of treat-to-target is that one does not decide on the level of therapy purely based on the patient's symptoms and signs. Instead, there is a pre-defined target that may incorporate clinical features and/or quantitative measurements. If the target is not achieved at a particular consultation then the therapy is changed. This works well in conditions such as hypertension and diabetes mellitus where there is a readily quantifiable measure (e.g. BP, HbA1c) that can be used as a target and where there is good evidence that not reaching that target could lead to worse long-term outcomes. The treat-to-target approach is now well-established in inflammatory arthritis. Development of treat-to-target guidelines in SLE is potentially more challenging because the condition is so heterogeneous. No single disease activity measure is universally agreed upon and different specialists may have different views about the ideal balance between disease activity and treatment side-effects. Between 2012 and 2013, however, a multi-disciplinary taskforce including patient involvement developed evidence-based treat-to-target guidelines for SLE. The over-arching principles were that decisions should be shared between the physician and the patient, that longterm follow-up and multi-disciplinary collaboration are important and that there should be several parallel targets rather than a single target. This led to 11 recommendations which were rated by 38 taskforce members with scores of > 9/10 agreement for each recommendation. The recommendations covered multiple issues, including achievement of low disease activity, prevention of disease flares and damage, recognizing and treating renal disease and anti-phospholipid syndrome, reduction of steroid dose to the minimum necessary to control disease activity, consideration of anti-malarial therapy and the importance of managing co-morbidities and factors affecting quality of life. Importantly, most of these could be addressed routinely in ordinary clinic consultations, making these guidelines a potential blueprint for management of SLE. Disclosure statement: A.R.: Other: member of an adjudication committee for a clinical trial run by Neovacs.
UPDATE ON ANKYLOSING SPONDYLITIS AND AXIAL SPONDYLOARTHRITIS I10. PATHOGENESIS OF AS, THE ROLE OF THE IL-17/23 AXIS
Paul Bowness
Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Science, University of Oxford, Oxford, UNITED KINGDOM Ankylosing Spondylitis is an immune-mediated rheumatic disease with a major genetic contribution and a likely ubiquitous environmental trigger. I will discuss the genes, immune cells, cytokines and implicate in AS. Possession of HLA-B27 is the strongest genetic contributor to AS. Recent GWAS studies have shown that ERAP polymorphisms are important in B27 þ cases (implicating antigen presentation) and have identified over 100 other genetic regions where variation predisposes to AS. Notably these include ERAP1 and several genes in the Th17 pathway. HLA-B27 may cause AS because it has an abnormal cell biology. Thus B27 can both misfold inside cells and form homodimers (B272) on the cell surface. Cell surface B272 may have a pathogenic role in SpA by binding Natural Killer family receptors. This interaction can result in IL-17 production. Th17 T cells are CD4 T cells that make the pro-inflammatory cytokine IL-17A. They also make other inflammatory cytokines (including IL-17F) and are themselves driven by IL-23. I will argue that this IL-17/23 axis is important in AS is now an important target for therapeutic drug and antibody development.
Understanding the immune pathogenesis of AS will give great opportunities for more effective targeted therapy. In turn the efficacy (or otherwise) of biologic therapies including anti-TNF and anti-Th17, in treatment trials gives invaluable information about the roles of these pathways in disease. 
I12. NSAIDS, CONVENTIONAL SYNTHETIC DMARDS AND BIOLOGICS IN SPA: THEIR ROLE AND IMPACT ON DISEASE OUTCOMES
Sofia Ramiro
Leiden University Medical Center, Leiden, THE NETHERLANDS Treatment options for patients with spondyloarthritis (SpA) are slowly expanding, which is reflected in the most recent ASAS-EULAR recommendations for the management of patients with axial SpA. Patients with non-radiographic axial SpA with signs of active inflammation can be eligible for treatment with biologic DMARDs (bDMARDs) if treatment with NSAIDs has failed. Patients with radiographic axial SpA with an indication for bDMARDs can now count with TNF inhibitors but also with IL-17 inhibitors. Current treatments recommended for axSpA have demonstrated improving several disease core outcomes, including disease activity, functional ability and quality of life. Inhibition of structural progression is one of the main aims of treatment in rheumatic inflammatory diseases. It is also what defines a drug as a DMARD. In axSpA we have been lacking interventions that fulfill this definition and inhibition of structural progression has been an unmet need. Notwithstanding, there are several particularities of axSpA and of the studies conducted that need to be taken into account when interpreting the existing data. In this presentation, the effect of NSAIDs, conventional synthetic and biologic DMARDs on several disease outcomes, among others structural progression, in patients with axSpA will be reviewed. Disclosure statement: The author has declared no conflicts of interest. The era of biologic treatment has changed the therapeutic landscape in rheumatology. In SLE, for the treatment of non-renal SLE, belimumab (anti-Blyss) is the only biologic that has been approved. The efficacy of belimumab in randomized clinical trials and in daily clinical practice will be discussed, including its efficacy in specific patient groups. Also, efficacy data from randomized trials with B-cell blocking agents will be highlighted. Recently, low disease activity and remission have been defined for SLE. Both items, among others, are treatment goals as stated in a consensus on treat-to-target for SLE. So, can these treat-to-target goals be reached with B cell blocking agents, and if so, how soon can these targets be reached? Disclosure statement: A.V. Honoraria: GlaxoSmithKline.
BIOLOGICS FOR LUPUS: HEARTBREAK HOTEL I13. A MILLION YEARS AGO
I15. REASONS TO BE CHEERFUL: ONE, TWO, THREE?
David Isenberg University College London, London, UNITED KINGDOM
The use of B-cell depletion and blocking B-cell activating factors has achieved varying degrees of success in patients with SLE. Benlysta which blocks the B-cell activating factor BAFF remains the only biologic to be formally approved in the UK and the USA for the treatment of lupus albeit under significant restrictions. Frustratingly, other approaches, for example, the use of Abatacept which blocks the antigen-presenting cell-T-cell interaction have not met their endpoints in clinical trials. Thus biologic therapy for lupus lags far behind that in patients with rheumatoid arthritis and psoriatic arthritis. Although ostensibly bleak, there is a growing conviction that some other biologic approaches may well work in SLE. For example, the importance of an increased interferon-alpha signature in the development of SLE is widely recognized. Three different monoclonal antibodies (Rontalizumab, Silfalimumab and Anifrolumab) have been used in major clinical trials in SLE. Rontalizumab failed to meet its primary endpoints but the other two drugs have done so in phase II trials albeit that they were focused on patients with skin and joint disease. This is perhaps the most promising alternative approach (to B-cell blockade) that we currently have. However other ongoing phase II trials utilizing a novel recombinant FcgIIB receptor (SM101) and RNP peptide (Lupuzor, previously known as PI140) are now under way after encouraging animal-model and/or phase I studies. In retrospect the significantly heterogeneous nature of lupus was always likely to make it more challenging to respond to individual biologic approaches.
However with an ongoing note of caution it seems that we may be, within the next five years, about to welcome some biologic drugs which do offer help to our hard-to-treat SLE patients. 
I17. ORAL DERMATOSES AND THE RHEUMATOLOGIST
Ruth Murphy
Dermatology, Royal Hallamshire Hospital, Sheffield, UNITED KINGDOM There are numerous oral signs which are relevant to rheumatology. In this talk I will cover the mucocutaneous manifestations of diseases which might present to rheumatology affecting the tongue, buccal mucosa, gingiva and lips. Both adults and children will be considered and emphasis will be given on how these signs aid diagnosis and direct disease management. Disclosure statement: The author has declared no conflicts of interest.
I18. PHOTOSENSITIVITY: IS IT LUPUS?
Robert Sarkany St John's Institute of Dermatology, London, UNITED KINGDOM Cutaneous photosensitivity occurs in many patients with systemic lupus erythematosus. In a patient with rheumatological and serological features suggestive of lupus, it is tempting to attribute photosensitivity to lupus and to add it in as evidence supporting the diagnosis of lupus.
The problem is that cutaneous photosensitivity is very common in the UK population, and has many possible causes other than lupus. It is important to establish whether the photosensitivity is due to lupus rather than another cause before adding photosensitivity to the evidence in favour of a diagnosis of SLE. 
GETTING INVOLVED IN COMMERCIAL RESEARCH I19. WHAT PHARMA COMPANIES WANT FROM THEIR PARTIAL LEAST SQUARES (PLS)
Theodore Reiss Research and Development, Celgene, Summit, NJ, USA
The innovation process, what we commonly call drug development, crosses many scientific and operational disciplines. Industry, university, government, patients and independent clinical investigators from around the world are part of this system. Therefore, the innovation process is an inherently interdependent, collaborative and translational; it is as time consuming as it is costly. Specifically, in clinical development, the clinical site investigator plays a critical role. The data generated in these clinical trials describing the benefit/risk profile of a new chemical entity are critical for regulatory review, pricing and reimbursement discussions, and methods of clinical use. High quality data are also critical to make decisions to stop a program, hopefully early in development. From the point of view of a pharma scientist, this talk will highlight these global issues, including the role, challenges and benefits of study sites and site investigators. Disclosure statement: The author has declared no conflicts of interest.
I20. SMALL IS BEAUTIFUL
David Walker
Freeman Hospital, Newcastle Hospitals NHS Trust, Newcastle upon Tyne, UNITED KINGDOM This presentation is of one way of managing to do commercial research with minimum personnel and investment. It will chronicle the changes and challenges to the service over the past 20 years and outline the benefits and risks involved.
Disclosure statement: The author has declared no conflicts of interest.
I21. BIG IS BETTER
Hasan Tahir Rheumatology, Spire Bushey Hospital, London, UNITED KINGDOM
No abstract submitted
IMMUNOLOGY: THE BASICS FOR TRAINEES I22. UNDERSTANDING THE IMMUNOLOGY OF AUTOIMMUNE CONNECTIVE DISEASES
David Isenberg
Rheumatology, University College London, London, UNITED KINGDOM Systemic lupus erythematosus (SLE) is a multifactorial disease -the consequence of a complex interplay between genetic factors, environmental effects, hormones and abnormalities in both the innate and adaptive immune systems. Critical to the development of SLE are disturbances in apoptotic cell clearance, cytokines, B-cell immunity and T-cell signaling. Over 40 different genetic disease susceptibility loci have now been identified in lupus patients among the best known are deficiencies in the components of the complement cascade especially the early parts of the pathway (e.g. C1q, C2). Genome-wide association studies have also strongly implicated other risk loci known as ITGAM, FcgR, PRDM1-ATG5 and TNFAIP3. Their precise contribution however remains unclear. Lupus has become recognized as a disease of faulty waste disposal. In other words there are defects in the removal of apoptotic cells. The events which initiate apoptosis are likely to include infection and ultraviolet radiation, but the key element is the failure of phagocytes to remove apoptetic materials and results in fragments of nuclear particles entering the circulation, being captured by antigen-presenting cells and through interactions with T and B-cells ultimately leading to the development of the variety of antinuclear antibodies typically present in the disease. Lupus is also associated with an intense activation of polyclonal Bcells. There is a population shift towards more immature B-cells that appear independent of disease activity. Other more complex abnormalities include disturbances in memory B-cells in the peripheral blood of patients with lupus, including CD27 þ /IgD-post-switched memory cells that are less susceptible to immunosuppression, whereas CD27 À /IgD-memory B-cells are increased and associated with disease activity in renal lupus. Some additional recent abnormalities in the so-called B-regulatory cells have also been identified. T-cells regulate B-cell responses and infiltrate target tissues causing damage. T-cells in patients with lupus are in a somewhat anergic state. Studies have shown defects in early and intermediate cell signaling, adhesion, co-stimulation, gene transcription and alternative splicing implying that T-cell dysfunction is also critically involved in disease pathogenesis. Disclosure statement: The author has declared no conflicts of interest.
I23. UNDERSTANDING THE IMMUNOLOGY OF INFLAMMATORY ARTHRITIS
Peter Taylor Rheumatology, University of Oxford, Oxford, UNITED KINGDOM The era of targeted therapies for the management of inflammatory arthritis arose out of two concurrent basic science advances over a generation ago. The first of these was an advance in protein engineering that gave rise to the ability to make monoclonal antibodies with specificity for a single protein target. Secondly, was the cataloguing and documentation of a role for various cells and proinflammatory mediators, in particular cytokines, in the pathobiology of inflammatory arthritis. Subsequent clinical trials unequivocally confirmed the importance of the particular therapeutic target in the pathology of a given disease. But furthermore, by using targeted biologic therapies as probes of pathogenesis, as well as investigating their efficacy in a range of inflammatory rheumatic disorders, it has become clear that while some pro-inflammatory mediators have a role in a wide variety of disease phenotypes, others are more restricted. For example, monoclonal antibodies targeting TNF have efficacy in inflammatory bowel disease (IBD), rheumatoid arthritis (RA), skin psoriasis (PsO), psoriatic arthritis (PsA) and ankylosing spondylitis (AS). IL6 inhibition is effective in rheumatoid arthritis and giant cell arteritis but less so in axial inflammation. IL17A inhibition has been shown to be effective in PsO, PsA and AS but not in RA. Similarly, IL23 is a key cytokine in the pathogenesis of PsO. In addition, understanding the roles of key components of the immune system such as B cell and T cells, how they become activated, and their role in the pathogenesis of inflammatory arthritis has given rise to targeted therapies directed to CD20 and co-stimulation pathways. In this lecture, we will explore the key cells and cytokines involved in inflammatory arthritis and how this knowledge might help inform a management choice. Disclosure statement: P.T.: Consultancies: UCB, Bristol-Myers Squibb, Pfizer, AbbVie, Sandoz, Biogen, Eli Lilly, Celgene, Novartis, Roche, GlaxoSmithKline. Grants/research support: Galapagos, Eli Lilly, UCB, Celgene, Janssen.
I24. UTILIZING IMMUNOLOGY: CURRENT AND EMERGING THERAPIES IN RHEUMATIC DISEASE
John Isaacs
Newcastle University, Newcastle University, Newcastle upon Tyne, UNITED KINGDOM
The last two decades have witnessed a revolution in the management of immune-mediated inflammatory diseases (IMID). In part this has been a consequence of new technologies, in particular biologic therapies. However, a key component has been a much deeper understanding of the immunology that underpins these conditions. In this lecture I will attempt to pull together elements of this therapeutic revolution. In part 1 will draw on lessons we can learn from nonrheumatic IMIDs such as psoriasis and inflammatory bowel disease, while keeping a focus on the everyday diseases encountered by rheumatologists. The key pathways I will mention are the IL23/IL17 axis, JAK/STAT pathways, and interferons. Disclosure statement: J.I.: Consultancies: Pfizer, Eli LIlly, Janssen, Celltrion, AbbVie, Bristol-Myers Squibb, Roche, Chugai, Hospira, Merck Serono. Member of speakers' bureau: Biogen, Roche, Pfizer. Grants/research support: Pfizer.
STAYING AT WORK: WORK ASSESSMENTS AND REHABILITATIVE INTERVENTIONS FOR PEOPLE WITH INFLAMMATORY ARTHRITIS I25. THE WORK EXPERIENCE SURVEY FOR RHEUMATIC CONDITIONS: EVIDENCE AND APPLICATIONS
Julie Keysor
Clinical Epidemiology Research and Training Unit, University of Boston, Boston, MA, USA Work disability rates are high among people with rheumatic and musculoskeletal conditions and efficacious disability preventive programs are needed. The Work Experience Survey for Rheumatic Conditions (WES-RC) is a checklist tool that guides consumers and health professionals in identifying and prioritizing common rheumatic work-related barriers. Once barriers are identified, the tool is used to guide a discussion to generate solutions to the work-related barriers encountered by the consumer. The WES-RC is included as one component of a broader intervention approach to enhance the ability of people with rheumatic and musculoskeletal conditions who are at risk of work loss remain employed. This presentation will discuss the WES-RC and two efficacious clinical trials that used the WES-RC as part of a broader intervention to prevent two year work loss. The first randomized trial showed a 40% reduction in work loss in the intervention group compared to the control. The intervention was delivered by trained vocational rehabilitation counselors and focused on job accommodation, self-advocacy for disability employment issues, and career counseling. In our recent clinical trial (ClinicalTrials.gov, NCT01387100) 287 participants were recruited from a large metropolitan area in the United States with self-reported doctor diagnosed chronic rheumatic or musculoskeletal conditions who were at risk of work loss. Thirty-six participants experienced permanent job loss at two years: 11 (8%) were intervention participants and 25 (18%) control participants (p¼.03). There was no difference, however, in the mean WLQ change scores from baseline to two year follow-up [À8.6 AE 1.9 intervention vs. À8. Work instability, a mismatch between a person's abilities and their job demands, and work disability, ceasing to work before retirement due to ill health, are high among people with inflammatory arthritis (IA). Work instability results in reduced productivity at work (presenteeism) and if unresolved, places individuals at an increased risk of work disability. These can both have major socio-economic and health consequences, both for the individual and the society as a whole. Once people are work disabled they are unlikely to return to work, therefore preventative strategies to help people stay in work may be a more effective approach than targeting return to work interventions in health and social care. Vocational rehabilitation (VR) is a process to overcome barriers to remaining in work and occupational therapists are best placed to provide VR due to their inherent skills in task analysis, dual training in psychological and physiological rehabilitation, understanding of environmental barriers and facilitators, and personcentred, biopsychosocial approach to treatment. This presentation will discuss the results of a feasibility Randomized Clinical Trial evaluating job retention VR for employed people with inflammatory arthritis, provided by Rheumatology occupational therapists in the UK. Implications for future research and clinical practice will be considered. Disclosure statement: Y.P.: Grants/research support: Arthritis Research UK Project Grant for the WORK-IA Project.
I27. BEHAVIOURAL COPING EFFORTS TO MANAGE WORKPLACE ACTIVITY LIMITATIONS
Monique Gignac
Institute for Work and Health, Toronto, ON, CANADA Background: Despite improved treatment, many individuals with inflammatory arthritis (IA) report difficulties working, reduced productivity and elevated absenteeism. Although interventions have begun to address workplace issues facing individuals with IA, few studies have examined existing workplace policies and whether their use is associated with better health and employment outcomes. This research) examined behavioural coping efforts used by individuals to manage health and work difficulties; the availability, need and use of diverse workplace policies, comparing those with arthritis to healthy controls and factors associated with coping efforts, including the intermittent nature of arthritis symptoms, the decision whether to disclose one's arthritis at work and work-health-life balance. Methods: Data are drawn from three studies of participants living with IA, osteoarthritis (OA) and healthy controls. Two community surveys (total n ¼ 1772) and one qualitative study (n ¼ 40) collected data. Study 1 participants were administered questionnaires on four separate occasions spanning $5 years using in-person interviews; study 2 participants were administered on-line questionnaires or surveyed by telephone; qualitative participants participated in one of eight focus groups. All studies assessed demographic (e.g., age, gender), health (e.g., pain, fatigue, workplace activity limitations) and work context (e.g., job sector, hours, physical work) information. Surveys also assessed workplace practices and accommodations (e.g., flexible hours, special equipment, modified duties), psychosocial perceptions (e.g. work-health balance, job stress) and job outcomes (e.g. absenteeism, productivity loss, job disruptions).
Results: Respondents working with arthritis reported significantly poorer health (pain, fatigue) than healthy controls. To manage workplace activity limitations, respondents reported a range of coping efforts, including giving up or modifying job activities, anticipating and avoiding problems and getting assistance from colleagues. Approximately, 20% of respondents changed jobs over the course of $5 years and 24-45% had not told their employer about their arthritis. Yet, there were few differences in reports of needing or using workplace policies compared to healthy controls and many individuals delayed using workplace accommodations until symptoms were consistently severe. Participants with arthritis who had unmet accommodation needs reported greater work stress, fatigue, workplace activity limitations, health variability, productivity loss and job disruptions. Respondents who drew upon workplace policies in advance of a problem or crisis had the lowest levels of fatigue, activity limitations, productivity loss and job disruptions. Conclusion: Despite poorer health, respondents with arthritis often did not take advantage of available workplace policies and many were reluctant to disclose activity limitations at work. Yet using accommodations, even when not needed, was associated with better health and work outcomes. These results need to be replicated. They point to potential benefits of more proactive use of work policies to manage arthritis and employment. 
I30. BARBARA ANSELL ADDRESS
Lucy Wedderburn
Great Ormond Street Institute of Child Health, University College London, London, UNITED KINGDOM I am both honoured and humbled to be asked to give the first BSR/ BSPAR Barbara Ansell Address. I knew Barbara when I was a new fellow in Paediatric Rheumatology, while she was still active within and highly supportive of, our then small but rapidly growing specialty. At that time, effective treatments for childhood arthritis were very few; children frequently acquired significant disability and spent much time as hospital in-patients, due to their arthritis. Much has changed since then. Our specialty has grown, become independent, and established the science of childhood autoimmune and auto-inflammatory rheumatic conditions. My laboratory has its central focus on the immunology of two autoimmune conditions of childhood, both of them heterogeneous and complex. The dissection of the mechanisms and biology that underlie childhood arthritis, and how those insights lead us to more targeted treatments, has been a key focus, as well as the discovery of tools which allow us to realize a stratified medicine approach to childhood arthritis. In parallel, we have studied juvenile dermatomyositis, aiming to develop a deeper understanding of the aetiopathogenesis of this complex, rare condition and propose new and more effective treatments. A common thread throughout has been the vital role of National and International collaborations, which continue to grow and flourish, and which are vital to enable us to make rapid progress towards better outcomes for children. In this talk I will review progress in our understanding in the biology of both of these complex conditions, and how these immunological insights can alter our management of childhood arthritis and myositis. 
